Navigation Links
The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
Date:8/23/2012

WHITE PLAINS, N.Y., Aug. 23, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced the awarding of 20 grants representing a total investment of $12 million to tackle four areas of high unmet medical need in the blood cancers.

In response to requests for proposals from researchers in these four critical areas, LLS is awarding these grants under its Translational Research Program, an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.

The RFPs mark LLS's aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs.  LLS aims to stimulate more academic research in these areas: the malignant stem cells in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS); non-cutaneous T-cell malignancies; high-risk myeloma; and long-term and late effects of blood cancer therapies. The grants recipients are:

  • The leukemic stem cell in AML and MDS and the identification of potential targeted therapies:
    • Alan D'Andrea, M.D., Dana-Farber Cancer Institute, Targeting ID1 in Acute Myeloid Leukemia Stem Cells
    • James Griffin, M.D., Dana-Farber Cancer Institute, Aberrant splicing in AML: novel molecular markers and therapeutic targets 
    • H. Leighton Grimes, Ph.D., Children's Hospital Medical Center of Cincinnati, RNA Therapeutics for Leukemia 
    • Monica Guzman, Ph.D., Joan & Sanford I. Weill Medical College of Cornell University, Strategies to eliminate leukemia stem cells during remission 
    • Duane Hassane, Ph.D., Joan & Sanford I. Weill Medical College of Cornell University, Significance and Mechanisms of Genomic Diversity in AML Stem Cells 
    • Anthony Letai, M.D., Ph.D.,  Dana-Farber Cancer Institute, Personalizing AML therapy by BH3 profiling AML stem cells 
    • Ross Levine, M.D., Memorial Sloan-Kettering Cancer Center, Targeting cytosine hydroxymethylation in AML stem cells 
    • A. Thomas Look, M.D., Dana-Farber Cancer Institute, Targeting of nuclear export in primary AML cells 
    • Li  Zhang, MSc, M.D., Ph.D, University Health Network,  Preventing AML relapse by targeting stem cells with double-negative T-cells 
  • Novel therapeutic strategies for non-cutaneous T-cell lymphoproliferative disorders:
    • Jaroslaw Maciejewski, M.D., Ph.D., Cleveland Clinic Foundation, Implications of STAT3 Mutations in Large Granular Lymphocyte Leukemia 
    • Owen O'Connor, M.D., Ph.D., Columbia University, Epigenetic Approaches to PTCL Therapy 
  • Development of therapeutic strategies for the high risk myeloma patient:
    • Jennifer Carew, Ph.D., University of Texas Health Science Center at San Antonio, Targeting SIRT1 in Multiple Myeloma 
    • Irene Ghobrial, M.D., Dana-Farber Cancer Institute, Targeting Hypoxic and Metabolic pathways in Multiple Myeloma 
    • Christoph Heuck, M.D., University of Arkansas for Medical Sciences, Targeting DNA methylation in the diagnosis and therapy of high-risk myeloma 
    • Alexander Stewart, M.D., Mayo Clinic, Development of Novel Therapeutics Targeting High Risk Myeloma 
  • Mechanisms underlying long term and late effects resulting from cancer treatment and the development of measures to significantly reduce or prevent these toxicities
    • Smita Bhatia, M.D., M.P.H., City of Hope, Bone Marrow Transplant Survivor Study-2
    • Eric Chow, M.P.H., Fred Hutchinson Cancer Research Center, Dexrazoxane and prevention of anthracycline-related cardiomyopathy 
    • Ruben Niesvizky, M.D., Joan & Sanford I. Weill Medical College of Cornell University, Stem cell alterations in lenalidomide treated myeloma patients 
    • Pavan Reddy, M.D., University of Michigan, Alpha 1-antitypsin as a novel strategy to modulate GVHD 
    • Daniela Salvemini, Ph.D, Saint Louis University, Blocking bortezomib induced painful peripheral neuropathy with FTY720 

LLS also announced the awarding of an additional 28 TRP grants, totaling $15.6 million, to scientists working in other areas of blood cancer research.

"By issuing RFP's LLS is taking a strategic approach to identifying and prioritizing areas of need and directing funding to research that shows the most promise for improving survival and quality of life for patients with these particularly difficult diseases," said Richard Winneker, Ph.D., LLS's SVP, Research.

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

Contact:  Andrea Greif
              (914) 821-8958 
              andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
2. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
3. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
4. MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
5. MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020
6. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
7. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
8. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
9. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
10. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
11. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):